Targeted radionuclide therapy for solid tumors: An overview

Sally J. DeNardo, Gerald L Denardo

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Although radioimmunotherapy (RIT) has been effective in non-Hodgkin's lymphoma (NHL) as a single agent, solid tumors have shown less clinically significant therapeutic response to RIT alone. The clinical impact of RIT or other forms of targeted radionuclide therapy for solid tumors depends on the development of a high therapeutic index (TI) for the tumor vs. normal tissue effect, and the implementation of RIT as part of synergistic combined modality therapy (CMRIT). Preclinical and clinical studies have provided a wealth of information, and new prototypes or paradigms have shed light on future possibilities in many instances. Evidence suggests that combination and sequencing of RIT in CMRIT appropriately can provide effective treatment for many solid tumors. Vascular targets provide RIT enhancement opportunities and nanoparticles may prove to be effective carriers for RIT combined with intracellular drug delivery or alternating magnetic frequency (AMF) induced thermal tumor necrosis. The sequence and timing of combined modality treatments will be of critical importance to achieve synergy for therapy while minimizing toxicity. Fortunately, the radionuclide used for RIT also provides a signal useful for nondestructive quantitation of the influence of sequence and timing of CMRIT on events in animals and patients. This can be readily accomplished clinically using quantitative high-resolution imaging (e.g., positron emission tomography [PET]).

Original languageEnglish (US)
JournalInternational Journal of Radiation Oncology Biology Physics
Volume66
Issue numberSUPPL. 2
DOIs
StatePublished - Oct 1 2006

Fingerprint

Radioimmunotherapy
Radioisotopes
radioactive isotopes
therapy
tumors
Neoplasms
time measurement
Therapeutics
sequencing
necrosis
toxicity
animals
positrons
delivery
drugs
Combined Modality Therapy
tomography
prototypes
nanoparticles
Positron-Emission Tomography

Keywords

  • CMRIT
  • MAb
  • RIT
  • Vascular leak

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Targeted radionuclide therapy for solid tumors : An overview. / DeNardo, Sally J.; Denardo, Gerald L.

In: International Journal of Radiation Oncology Biology Physics, Vol. 66, No. SUPPL. 2, 01.10.2006.

Research output: Contribution to journalArticle

@article{9f0478d1b4a142439b287a4db7622b81,
title = "Targeted radionuclide therapy for solid tumors: An overview",
abstract = "Although radioimmunotherapy (RIT) has been effective in non-Hodgkin's lymphoma (NHL) as a single agent, solid tumors have shown less clinically significant therapeutic response to RIT alone. The clinical impact of RIT or other forms of targeted radionuclide therapy for solid tumors depends on the development of a high therapeutic index (TI) for the tumor vs. normal tissue effect, and the implementation of RIT as part of synergistic combined modality therapy (CMRIT). Preclinical and clinical studies have provided a wealth of information, and new prototypes or paradigms have shed light on future possibilities in many instances. Evidence suggests that combination and sequencing of RIT in CMRIT appropriately can provide effective treatment for many solid tumors. Vascular targets provide RIT enhancement opportunities and nanoparticles may prove to be effective carriers for RIT combined with intracellular drug delivery or alternating magnetic frequency (AMF) induced thermal tumor necrosis. The sequence and timing of combined modality treatments will be of critical importance to achieve synergy for therapy while minimizing toxicity. Fortunately, the radionuclide used for RIT also provides a signal useful for nondestructive quantitation of the influence of sequence and timing of CMRIT on events in animals and patients. This can be readily accomplished clinically using quantitative high-resolution imaging (e.g., positron emission tomography [PET]).",
keywords = "CMRIT, MAb, RIT, Vascular leak",
author = "DeNardo, {Sally J.} and Denardo, {Gerald L}",
year = "2006",
month = "10",
day = "1",
doi = "10.1016/j.ijrobp.2006.03.066",
language = "English (US)",
volume = "66",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Targeted radionuclide therapy for solid tumors

T2 - An overview

AU - DeNardo, Sally J.

AU - Denardo, Gerald L

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Although radioimmunotherapy (RIT) has been effective in non-Hodgkin's lymphoma (NHL) as a single agent, solid tumors have shown less clinically significant therapeutic response to RIT alone. The clinical impact of RIT or other forms of targeted radionuclide therapy for solid tumors depends on the development of a high therapeutic index (TI) for the tumor vs. normal tissue effect, and the implementation of RIT as part of synergistic combined modality therapy (CMRIT). Preclinical and clinical studies have provided a wealth of information, and new prototypes or paradigms have shed light on future possibilities in many instances. Evidence suggests that combination and sequencing of RIT in CMRIT appropriately can provide effective treatment for many solid tumors. Vascular targets provide RIT enhancement opportunities and nanoparticles may prove to be effective carriers for RIT combined with intracellular drug delivery or alternating magnetic frequency (AMF) induced thermal tumor necrosis. The sequence and timing of combined modality treatments will be of critical importance to achieve synergy for therapy while minimizing toxicity. Fortunately, the radionuclide used for RIT also provides a signal useful for nondestructive quantitation of the influence of sequence and timing of CMRIT on events in animals and patients. This can be readily accomplished clinically using quantitative high-resolution imaging (e.g., positron emission tomography [PET]).

AB - Although radioimmunotherapy (RIT) has been effective in non-Hodgkin's lymphoma (NHL) as a single agent, solid tumors have shown less clinically significant therapeutic response to RIT alone. The clinical impact of RIT or other forms of targeted radionuclide therapy for solid tumors depends on the development of a high therapeutic index (TI) for the tumor vs. normal tissue effect, and the implementation of RIT as part of synergistic combined modality therapy (CMRIT). Preclinical and clinical studies have provided a wealth of information, and new prototypes or paradigms have shed light on future possibilities in many instances. Evidence suggests that combination and sequencing of RIT in CMRIT appropriately can provide effective treatment for many solid tumors. Vascular targets provide RIT enhancement opportunities and nanoparticles may prove to be effective carriers for RIT combined with intracellular drug delivery or alternating magnetic frequency (AMF) induced thermal tumor necrosis. The sequence and timing of combined modality treatments will be of critical importance to achieve synergy for therapy while minimizing toxicity. Fortunately, the radionuclide used for RIT also provides a signal useful for nondestructive quantitation of the influence of sequence and timing of CMRIT on events in animals and patients. This can be readily accomplished clinically using quantitative high-resolution imaging (e.g., positron emission tomography [PET]).

KW - CMRIT

KW - MAb

KW - RIT

KW - Vascular leak

UR - http://www.scopus.com/inward/record.url?scp=33748443171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748443171&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2006.03.066

DO - 10.1016/j.ijrobp.2006.03.066

M3 - Article

C2 - 16979448

AN - SCOPUS:33748443171

VL - 66

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - SUPPL. 2

ER -